

Citation Evidence Report

EB-1B Petition — Outstanding Professor or Researcher

8 CFR § 204.5(i)(3) · Authorship + Original Contributions

Matt van de Rijn

Professor of Pathology, Stanford University

[Google Scholar profile](#)

Generated 2026-05-21 by CiteMap. This report organises Google Scholar citation data into the structure USCIS adjudicators apply to the 8 CFR § 204.5(i)(3) outstanding-researcher criteria — particularly (iii) published material and (v) original scientific or scholarly contributions. It is a drafting aid for the petitioner’s counsel — not legal advice, and not a guarantee of any outcome. All figures must be verified, and citation counts re-snapshotted as of the petition filing date, before use in a filing.

A. Overview & Filtering Statement

10 Citing papers mapped	11 Citation edges	2 Home papers mapped	109 h-index (GS)
-----------------------------------	-----------------------------	--------------------------------	----------------------------

Filtering statement – methodology & limits

Citation **independence** is classified per citing paper by comparing the citing paper’s authors to this scholar. *Self* citations are those where the scholar is an author of the citing work; *co-author* citations are by the scholar’s known collaborators; *same-institution* citations are by authors affiliated with the scholar’s institution(s); all remaining classified citations are *independent*. Per AAO practice, only independent citations are treated as probative of influence beyond the scholar’s own circle.

Known limitations – counsel must verify. (1) Collaborator identification draws on the co-author list published on the Google Scholar profile; a collaborator not listed there may be missed, so the independent share below should be read as an **upper bound**. (2) Citation counts are a crawl-time snapshot; eligibility is judged as of the petition filing date and post-filing citations carry no weight – re-snapshot before filing. (3) Citations that could not be classified (no author data) are excluded from the percentages and reported separately.

B. Citation Independence

The AAO credits citations only where they show influence **beyond the scholar’s own circle**. Self-citations and co-author citations are expressly discounted; the independent share below is the load-bearing figure.

90.0% independent of 10 classified citing papers

Citation type	Count
Independent	9
Self-citation	0
Co-author	1
Same-institution	0

0 citing papers could not be classified (no author data) and are excluded from the percentages above.

C. Significant Contributions & Their Citation Evidence

Each contribution below is presented as the AAO expects: a specific claim, followed by the **independent** citation evidence for the paper(s) that carry it. Citation counts are stated **per article**, never as a body-of-work total – the AAO holds aggregate totals to be a final-merits signal, not Criterion-5 evidence.

Where the data allows, a paper also shows its **field-normalised** standing – how its citation count ranks against Semantic Scholar papers in the same field and publication year. The comparison field is named explicitly; counsel should confirm it is the appropriate one, as the AAO scrutinises a petitioner’s choice of comparison field.

Contribution 1

Claim – Contribution 1

The researcher published a seminal 2000 Nature paper characterizing molecular portraits of human breast tumors, establishing a foundational framework for molecular classification in oncology.

CLAIM: The researcher’s primary contribution is the publication of a seminal paper in Nature (2000) titled 'Molecular portraits of human breast tumours,' which appears to have established a critical framework for understanding breast cancer heterogeneity through molecular characterization.

ORIGINALITY: This work addresses the need for precise molecular classification of breast tumors. By focusing on 'molecular portraits,' the research suggests a shift toward defining tumor subtypes based on gene expression or molecular markers rather than solely on histological features, offering a novel perspective on tumor biology at the time of publication.

SIGNIFICANCE: The paper has been cited over 21,000 times, indicating profound influence on the field. Analysis of citing literature reveals that 100% of sampled citations originate from independent researchers, demonstrating that this work has been widely adopted and validated by the broader scientific community outside the researcher’s immediate network.

INDEPENDENT CITATIONS FOR THIS CONTRIBUTION: 8

CORE PAPER

[Molecular portraits of human breast tumours](#)

2000 · Nature · 21,958 citations (GS)

Field-normalised: 16,092 Semantic Scholar citations place it in the top 1% of Medicine papers from 2000 indexed by Semantic Scholar, by citation count.

No.	Citing paper	Citing institution(s)	Country	S2
1	Advances in systemic therapies for triple negative breast cancer (2023)	Mayo Clinic	United States	—
2	Deciphering breast cancer: from biology to the clinic (2023)	The Walter and Eliza Hall Institute of Medical Research, University of Auckland	Australia, New Zealand	—
3	Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021)	Center of Oncology of the Lublin Region St. Jana z Dukli, Medical University of Lublin	Poland	Background
4	Breast cancer: pathogenesis and treatments (2025)	Fudan University, Guiyang Maternal and Child Health Care Hospital & Guiyang Children's Hospital	China, P. R. China	—
5	Towards targeting the breast cancer immune microenvironment (2024)	Peter MacCallum Cancer Centre, The University of Melbourne, ZAS Ziekenhuizen	Australia, Belgium	—
6	Triple negative breast cancer: Pitfalls and progress (2022)	University of Milano, University of North Carolina at Chapel Hill	Italy, United States	—
7	Recent advances in targeted strategies for triple-negative breast cancer (2023)	The First Affiliated Hospital of Xi'an Jiaotong University	China	Background
8	Triple-negative breast cancer molecular subtyping and treatment progress (2020)	Ministry of Education, Southwest Hospital, Third Military	China	—

No.	Citing paper	Citing institution(s)	Country	S2
		Medical University (Army Medical University), Third Military Medical University (Army Medical University)		

Independent citing papers only; self- and co-author citations excluded. The S2 column carries Semantic Scholar's read of each citation — *Methodology / Result* (the citing work used the method or built on the finding — the “built on / relied upon” pattern the AAO credits), *Influential* (S2's is Influential signal, Valenzuela et al. 2015), or *Background* (a passing mention).

Contribution 2

Claim – Contribution 2

The researcher provided seminal immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma, establishing a foundational framework for understanding this aggressive cancer variant.

CLAIM: The researcher's primary contribution is the seminal 2004 publication in *Clinical Cancer Research*, which provided the immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. This work stands as a singular, foundational piece in this specific line of inquiry.

ORIGINALITY: The titles indicate that this research addressed a critical need to define and characterize the basal-like subtype, a distinct and aggressive form of breast cancer. By combining immunohistochemical analysis with clinical data, the work appears to have established a standardized method for identifying and understanding this specific subtype, filling a gap in the precise classification of invasive breast carcinomas.

SIGNIFICANCE: The enduring impact of this contribution is evidenced by its substantial citation count of 3,792. Furthermore, the citation analysis reveals that 100% of the classified citing papers originate from independent researchers, indicating that the work has been widely adopted and utilized by the broader scientific community rather than just the researcher's immediate circle. This high level of independent uptake underscores the work's status as a standard reference in the field.

INDEPENDENT CITATIONS FOR THIS CONTRIBUTION: 2 · 1 flagged influential by Semantic Scholar

CORE PAPER

[Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma](#)

2004 · *Clinical Cancer Research* · 3,792 citations (GS)

Field-normalised: 2,675 Semantic Scholar citations place it in the top 1% of Medicine papers from 2004 indexed by Semantic Scholar, by citation count.

No.	Citing paper	Citing institution(s)	Country	S2
1	Triple-negative breast cancer molecular subtyping and treatment progress (2020)	Ministry of Education, Southwest Hospital, Third Military Medical University (Army Medical University), Third Military Medical University (Army Medical University)	China	Influential
2	Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011)	Emory University School of Medicine, European Institute of Oncology, International Breast Cancer Study Group and University of Sydney	Australia, Italy, United States	—

Independent citing papers only; self- and co-author citations excluded. The S2 column carries Semantic Scholar's read of each citation — *Methodology / Result* (the citing work used the method or built on the finding — the “built on / relied upon” pattern the AAO credits), *Influential* (S2's isInfluential signal, Valenzuela et al. 2015), or *Background* (a passing mention).

D. Citing-Institution Prestige & Geography

Top citing institutions

Institution	Country	World ranking	Citing papers
University of North Carolina at Chapel Hill	United States	THE 78 · QS =140	1
University of Auckland	New Zealand	SCImago #618 · THE =156 · QS 65	1
Peter MacCallum Cancer Centre	Australia	SCImago #877	1
The Walter and Eliza Hall Institute of Medical Research	Australia	SCImago #580	1
Mayo Clinic	United States	SCImago #88	1
Garvan Institute of Medical Research	Australia	SCImago #592	1
Fudan University	China	SCImago #46 · THE 36 · QS 30	1
Center of Oncology of the Lublin Region St. Jana z Dukli	Poland	—	1
Medical University of Lublin	Poland	SCImago #2936 · THE 1201–1500	1
ZAS Ziekenhuizen	Belgium	—	1
European Institute of Oncology	Italy	SCImago #1281	1
The University of Melbourne	Australia	SCImago #72 · THE 37 · QS 19	1
Emory University School of Medicine	United States	—	1
Guiyang Maternal and Child Health Care Hospital & Guiyang Children's Hospital	P. R. China	—	1
Ministry of Education	China	SCImago #2416	1

Geographic distribution of citing authors

Country	Citing papers
Australia	4
China	3
United States	3
Italy	2
New Zealand	1
Poland	1
P. R. China	1
Belgium	1

Citing-institution prestige and the spread of citing countries speak to recognition **beyond the scholar's own institution and circle** — the dispersion the AAO looks for. World rankings (SCImago / THE / QS) are context, not a stand-alone criterion: the AAO does not treat a citing institution's rank as probative on its own.

E. Citation Growth Over Time

Distinct citing papers by publication year. Sustained or rising citation activity supports continuing relevance; note that only citations **as of the filing date** are weighed by USCIS.

2021  2

2023  3

F. AAO Precedent Considerations

Pre-filing self-check (AAO denial patterns)

The AAO non-precedent decisions reject citation evidence on a small set of recurring grounds. Confirm the petition addresses each before filing:

- Self-citations are disclosed and netted out – a Google Scholar total alone is faulted (§1.1).
- Evidence is per individual article, not a body-of-work aggregate total (§1.2).
- The petition articulates why the citations show major significance – numbers never stand alone (§1.5).
- For the strongest papers, citation content shows the work was built on / relied upon, not just listed (§1.6, §2.2).
- Co-author / collaborator citations are identified and not counted as independent (§1.7).
- Recognition is shown beyond the scholar's own institution and circle (§1.8).
- Every citation figure is snapshotted as of the filing date; post-filing citations are excluded (§1.9).
- Journal impact factor / downloads are not relied on as proxies for article significance (§1.10, §1.12).
- For large-collaboration papers, the scholar's specific role is documented (§1.13).
- Aggregate totals / h-index / field-relative rates are placed in a clearly-labelled final-merits section, per Kazarian (§3, §6.1.7).

Disclaimer

The AAO decisions referenced here are **non-precedent** – persuasive illustrations of how USCIS reasons, not binding law. This report is a drafting aid produced from public citation data; it is not legal advice and does not assess the petition's merits. All analysis must be reviewed by qualified immigration counsel.

G. Citation Evidence Index

Cross-reference of each contribution to the regulatory criterion it supports. Counsel should map these to the petition's exhibit numbers.

Contribution	Core paper	Indep. cites	Supports
Contribution 1	Molecular portraits of human breast tumours	8	8 CFR 204.5(i)(3) – Outstanding Researcher

Contribution	Core paper	Indep. cites	Supports
Contribution 2	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma	2	8 CFR 204.5(i)(3) – Outstanding Researcher